NEWS AND EVENTS
-First study has begun enrolling patients to evaluate twice-daily formulation- -Second study to begin in the second quarter to assess once-daily dosing with the novel QD formulation- -Issuance of U.S. Patent No. 9,907,767 further expands Velicept’s patent portfolio covering Solabegron- MALVERN, PA – March 19, 2018 – Velicept Therapeutics, a privately-held specialty pharmaceutical company dedicated […]
Velicept Therapeutics, Inc. announced today Clarence Young, M.D. has joined its leadership team as the company’s Chief Medical Officer.
Malvern, PA, October 5, 2016 (BUSINESS WIRE) – Velicept Therapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted an Investigational New Drug (IND) application to initiate a Phase I pharmacokinetic study for a once-daily formulation for solabegron.